EPIDEMIOLOGY OF VENOUS THROMBOSIS AND PULMONARY EMBOLISM

描述：（改编自研究者摘要）静脉血栓栓塞， 包括深静脉血栓形成（DVT）和肺栓塞（PE），是一种 是美国发病率和死亡率的主要原因。 然而，没有全面的，前瞻性的，以人群为基础的流行病学研究。 研究同时检查了生活方式、分子和生物化学 这一重要疾病的危险因素。 拟议项目将 在两个仔细进行的研究中有效地研究了静脉血栓栓塞症 非裔美国人和白色成年人的前瞻性流行病学研究-- 社区动脉粥样硬化风险（ARIC）研究和心血管疾病 健康研究。 其目标如下： 1)识别和确认DVT和PE病例，以估计事件 ARIC和CHS合并患者的住院静脉血栓栓塞率 队列; 2)前瞻性地确定静脉血栓栓塞与 人口统计学和生活方式因素、血脂、病史，以及 止血成分（包括纤维蛋白原、血小板计数、因子VIIc 和VIIIc）使用现有的ARIC和CHS数据;以及 3)使用储存的诊断前血液进行巢式病例对照研究 和DNA标本，以确定静脉 血栓栓塞与以下：促凝血剂或抗凝剂水平 因子和相关遗传变异（包括因子V Leiden）， 纤维蛋白溶解因子（例如，纤溶酶原激活物抑制剂-1）和相关 遗传变异、凝血酶活化标记物和其他潜在的 重要的生物化学或相关遗传因素（例如，同型半胱氨酸）。 研究人员指出，同时测量这些 生活方式，分子和生化因素，以及对它们的估计 在一项全面的前瞻性研究中， 提供了重要的流行病学见解的病因静脉 血栓栓塞

DESCRIPTION: (Adapted from Investigator's Abstract) Venous thromboembolism, comprising deep venous thrombosis (DVT) and pulmonary embolism (PE), is a major contributor to morbidity and mortality in the United States. Nevertheless, no comprehensive, prospective, population-based epidemiologic studies have simultaneously examined lifestyle, molecular, and biochemical risk factors for this important disease. The proposed project will efficiently investigate venous thromboembolism in two carefully conducted prospective epidemiologic studies of African American and white adults -- the Atherosclerosis Risk in Communities (ARIC) Study and the Cardiovascular Health Study (CHS). The aims are as follow: 1) to identify and validate DVT and PE cases, in order to estimate incident rates of hospitalized venous thromboembolism in the combined ARIC and CHS cohorts; 2) to determine prospectively the association of venous thromboembolism with demographic and lifestyle factors, plasma lipids, medical history, and hemostatic components (including fibrinogen, platelet count, factors VIIc and VIIIc) using existing ARIC and CHS data; and 3) to conduct a nested case control study using stored pre-diagnosis blood and DNA specimens to determine the prospective associations of venous thromboembolism with the following: levels of procoagulant or anticoagulant factors and related genetic variants (including factor V Leiden), fibrinolytic factors (e.g., plasminogen activator inhibitor-1) and related genetic variants, markers of thrombin activation, and other potentially important biochemical or related genetic factors (e.g., homocysteine). The investigators point out that the concurrent measurement of these lifestyle, molecular, and biochemical factors, and estimation of their relative and attributable risks in a comprehensive prospective study, will provide important epidemiologic insights into the etiology of venous thromboembolism.